Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia.
Department of Medicine, University of Arizona, Tucson.
Seongseok
S
Yun
Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Nicole D
ND
Vincelette
Arizona Cancer Center, University of Arizona, Tucson4Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson.
Ivo
I
Abraham
D066126:Cardiotoxicity / Q000503:physiopathology; D018376:Cardiovascular Abnormalities / Q000139:chemically induced / Q000503:physiopathology*; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate